Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.45 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1245066 | 0.89 | RAB9A (0.51) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1244568 | 0.88 | ALOX15 (0.55) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL4393058 | 0.84 | DAO (0.47) | KDM4EALDH1A1HPGDLMNAMAPT | |
| SCHEMBL15850382 | 0.83 | ALDH1A1 (0.51) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL69116 | 0.80 | HPGD (0.58) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL18034454 | 0.77 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1244713 | 0.77 | ALDH1A1 (0.54) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1244117 | 0.77 | KDM4E (0.51) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL6625018 | 0.75 | KDM4E (0.49) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL1244590 | 0.74 | RAB9A (0.51) | KDM4EALDH1A1HPGDRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306169-A1 | Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors | BRANDISH PHILIP E | 2009-12-10 | — | — | US | disclosed |
| EP-1942885-A1 | USE OF FUSED PYRROLE CARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES AS D-AMINO ACID OXIDASE INHIBITORS | MERCK SHARP & DOHME LTD. (GB) | 2008-07-16 | — | — | EP | disclosed |
| WO-2007039773-A1 | USE OF FUSED PYRROLE CARBOXYLIC ACIDS FOR THE TREATMENT OF NEURODEGENERATIVE AND PSYCHIATRIC DISEASES AS D-AMINO ACID OXIDASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306169-A1 | Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors | DAO, DDO, MAOB | KDM4E 1526/4885ALDH1A1 337/4885HPGD 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.